<DOC>
	<DOCNO>NCT01906255</DOCNO>
	<brief_summary>This observational nested case control study among pre-exposure prophylaxis ( PrEP ) observational clinical study . The study assess level adherence measure drug level relationship renal bone adverse event , risk seroconversion , resistance development subject take emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) ( Truvada® ) PrEP . In protocols parent PrEP observational clinical study , participant follow-up visit average every 3 month evaluation adherence , HIV-1 status , renal bone adverse event , seroconversion . Adherence determine specific FTC/TDF drug level measurement ( ) outline parent protocol . There two case definition : ) One-hundred-fifty subject seroconvert ( become HIV-1 positive ) b ) subject either develop protocol-defined renal adverse event ( stratified Division AIDS [ DAIDS ] grade ) skeletal adverse event ( fracture ) take FTC/TDF PrEP . Among estimate 7,000 subject Truvada PrEP observational clinical study case , defined subject seroconvert and/or develop either renal skeletal adverse event , identify . Randomly chosen control Truvada select 3:1 ratio , site , similar treatment duration .</brief_summary>
	<brief_title>Seroconversions , Resistance , Adverse Events Drug Adherence Among Subjects Taking Truvada® PrEP : A Case Control Study</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Participants FTC/TDF PrEP observational clinical study HIV1 negative adult ( sex/gender , include transgender ) FTC/TDF PrEP observational clinical study HIV1 negative without sign symptom acute HIV1 infection This observational study monitor report seroconversions , renal skeletal adverse event without intervention/exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Truvada</keyword>
	<keyword>FTC/TDF</keyword>
	<keyword>Pre-exposure prophylaxy</keyword>
	<keyword>PrEP</keyword>
	<keyword>Adherence</keyword>
	<keyword>Resistance</keyword>
</DOC>